The research group is co-led by Dr José Domínguez (MSc, PhD; consolidated from the Miguel Servet Programme) and Dr Cristina Prat-Aymerich (MD, PhD), both of them senior researchers and clinical microbiologists. Currently, Dr Cristina Prat-Aymerich is on work leave from HUGTiP clinical position and is holding a position of assistant professor in University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, Utrecht, Netherlands.
The group is located at the Institut de Recerca Germans Trias i Pujol (IGTP); Hospital Universitari Germans Trias i Pujol (HUGTiP) and Universitat Autònoma de Barcelona (UAB) (Genetics and Microbiology Department, Biosciences Faculty); and it is affiliated with the CIBERES network (CB06/06/0031). The group is recognized by the Generalitat of Catalonia as Grup de Recerca Consolidat (2017SGR-0492 and 2021SGR-1267). Thanks to this recognition, the team has consolidated its activity and future perspectives. At this moment, the group has scientifically grown up, and has developed solid and productive independent own research lines. The consolidation of the research lines is consequence of the vocation of integrating clinical and translational research in our activities.
The researchers’ work is also performed in collaboration and in tight coordination with the departments of Microbiology, Pediatrics, Pneumology, Intensive Care, Emergency and the Preventive Medicine at the Germans Trias University Hospital. Some members of the SGR Group are located outside the Can Ruti Campus: in the Tuberculosis Unit Vall d'Hebron-Drassanes of the Hospital Universitari Vall d'Hebron, and in the Pulmonology Department of the Hospital Moises Broggi.
Keywords: Diagnostic, Microbial interaction, Environmental factors, Therapies.
Jose Antonio Dominguez Benitez(ELIMINAR)
Alicia Lacoma De La Torre(ELIMINAR)
Irene Latorre Rueda(ELIMINAR)
Sergio Diaz Fernandez(ELIMINAR)
Guillem Safont Gonzalez(ELIMINAR)
The group is working in the field of the respiratory infections and tuberculosis, improving the understanding of host-pathogen interactions, and exploring new approaches in diagnosis and therapies.
The scientific challenges and strategic objectives for the next 3 years are described below for each line of research, which will contribute to consolidating excellent research, promoting knowledge transfer and increasing the internationalization of the group.
Our research explores the microbial mechanisms of adaptation to the respiratory tract and related aspects of clinical presentation together with specific phenotypic and genotypic traits of microorganisms; using novel bioinformatic and genomic approaches. Research is mostly focused in Staphylococcus aureus and Mycobacterium tuberculosis, but Pseudomonas aeruginosa and Haemophilus influenzae have been also studied for aspects such as carrier status versus colonization versus infection in the respiratory tract. The objective is to identify differential factors that will allow the design of diagnostic tools to distinguish colonization from infection, in order to optimize treatment, to design novel targets and improved drug delivery systems that will contribute to treatment success and to reduce the emergence of antimicrobial resistance in lower respiratory tract infections.
Immune response characterization
We study the diagnostic and prognostic importance of inflammation markers in different infectious diseases and clinical syndromes, in collaboration with several Hospital Departments. We also study the host immune response to different antigens specific of M. tuberculosis to better characterize the latency state and to be able to find new biomarkers useful for identifying infected individuals with a higher risk of progressing to disease. The Group has experience in the study of the immune response by flow cytometry, studies on the characterization of different cellular subsets, and for a better understanding of S. aureus interaction with neutrophils, and also now SARS-CoV-2 infection.
Impact of external factors
We have consolidated the 2D in vitro model of intracellular persistence in murine/human alveolar macrophages, which permits us to carry out trials to explore the impact of tobacco smoke, e-vapor of e-cigarette, and diesel exhaust particles in the persistence of M.tuberculosis and also S.aureus. We have also studied the impact of tobacco smoking in the immune response against bacteria, and how the bacteria modify the phenotype for adapting to the toxic environment produced by the tobacco.
Diagnostic technology innovation
We are using molecular, metabolomics and immunological techniques for developing innovative diagnostic technologies. We are also developing and evaluating new molecular methods for studying mutations associated with resistance to anti-TB drugs. In this sense, we are leading an EU-H2020 consortium (INNOVA4TB) where one of the main objectives is to develop innovative technology. In the last years we have patented three technologies and licensed two of them.
New therapeutic approaches
We are carrying out studies involving the search and refinement of anti-infective drugs, but also the use of novel drug delivery systems loaded with conventional S. aureus and M. tuberculosis drugs. Conventional in vitro susceptibility studies are performed; and nanoparticles efficacy are also tested in infection cell models. These nanoparticles are produced by the group of Dr. Manuel Arruebo (Universidad de Zaragoza, Spain) in the framework of the TARMAC consortium, funded by CIBERES, CIBER-BBN and SEPAR.
Innovation for TB. INNOVA4TB
Funding entity: H2020-MSCA-RISE-2018. Ref. 823854
From: 2019 to: 2024
PI: J. Domínguez
Evaluar la utilidad de una nueva técnica en el diagnóstico de las infecciones por micobacterias no tuberculoses Ref. 18/691
Funding entity: Sociedad Española de Neumología y Cirugía Torácica
From: 2019 to: 2023
PI: J. Domínguez
Tuberculosis: Development of new diagnostic methods, new host-direct therapies and understanding the impact of extrinsic factors in modulating inflammation (INNOVA2)
Funding entity: Instituto de Salud Carlos III. PI19/01408
From: 2020 to: 2024
Pneumococcal pNeumonia Epidemiology, Urine serotyping, and Mental Outcomes. The PnEUmo Study in Europe (PNEUMO)
Funding entity: University Medical Center Utrecht. Ref. 820755
From: 2020 to: 2023
Central PI: M. Bonten. Scientific Coordinator C. Prat Aymerich
PI HUGTiP: A. Lacoma and F. Armestar
Multi-centre EuRopean study of MAjor Infectious Disease Syndromes (MERMAIDS) - Acute Respiratory Infections (MERMAIDS ARI) 2.0. ClinicalTrials.gov identifier NCT04364711
Part of the Consortium Rapid European COVID19 Research Response (RECOVER).
Coordinator: Herman Goossens
Funding entity: European Union's Horizon 2020 research and innovation programme under grant agreement No 101003589https://www.recover-europe.eu/
Consortium coordinator: Herman Goossens
Sponsor Europe: UMC Utrecht PI: Patricia Bruijning. Coordinating investigator: C. Prat-Aymerich
PI HUGTiP: Zoran Stojanovic
BCG vaccination to Reduce the impact of COVID-19 in healthcare workers following Coronavirus Exposure (BRACE) Trial. HREC/protocol no: 62586 NCT04327206. EUDRACT 2020-002503-19
Funding entity: Bill and Melinda Gates.
Chief PI: Nigel Curtis, Murdoch's Children Research Institute Melbourne Australia.
Sponsor Europe: UMC Utrecht
PI Europe: Marc Bonten. Role C.Prat-Aymerich: coordinating investigator (Netherlands and Spain)
PI HUGTiP: Antoni Rosell Gratacós
Point-of-care tests for the rapid detection of SARS-CoV-2 (POC4CoV)
Financing entity: Fondo COVID-19. Instituto de Salud Carlos III. Reference: 202050E090
From: 2020 to: 2021
PI: Maria Pilar Marcos
ChildTB-Omics: Omics for diagnosis of tuberculosis in children and adolescents
Financing entity: Fondo de Investigaciones Sanitarias. Instituto de Salud Carlos III
Grant reference: PI20/01607
From: 2021 to: 2024
PI: Begoña Santiago
Innovative tools to study the impact and mode of action of micro and nanoplastics on human health: towards a knowledge base for risk assessment (PLASTICHEAL)
Financing entity: H2020-SC1-2020-Single-Stage-RTD. Reference: 965196
From: 2021 to: 2024
PI: Ricard Marcos
Caracterización de la respuesta inmune en el manejo de la infección por SARS-CoV-2
Funding entity: Spanish Society of Pulmonology and Thoracic Surgery (SEPAR)
From: 2021 to: 2024
PI: Irene Latorre
Deep immune profiling of Mycobacterium tuberculosis local and systemic cell response - TB-IMMUN
Financing entity: Instituto de Salud Carlos III. PI21/00724
From: 2021 to: 2024
PI: Irene Latorre
A multinational, phase 2, randomized, adaptative protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines administration in older adults (>75) already vaccinated against SARS-CoV-2 (EU-COVAT-1_AGED). EudraCT nº. 2021-004526-29
Part of the European Clinical Research Network for the coordination and condult of COVID-19 vaccine trials (VACCELERATE)
Funding entity: Horizon 2020 Grant agreement number: 101037867
Coordinator: Prof. Oliver A. Cornely
Sponsor: University of Cologne (Germany)
PI HUGTiP: José Moltó. Laboratory Lead: José Domínguez
A Phase 2, Comparative Randomised Trial to Evaluate the impact of reduced COVID-19 mRNA vaccination regimens on immunological responses and reactogenicity in paediatric subjects with and without prior SARS-CoV-2 infection (CoVacc)
Funding: European Union H2020-IBA-SC1-CORONAVIRUS-2020-4. Consortium VACCELERATE. Grant agreement number 101037867
Sponsor: UMC Utrecht (Netherlands)
Central PI: Patricia Bruijning-Verhagen. Role C.Prat: Lead Medical Monitor
ADEQUATE Advanced Diagnostics for Enhanced QUality of Antibiotic prescription in respiratory Tract infections in Emergency rooms
Consortium VALUE Dx the value of diagnostics. Coordinator. Herman Goossens
Funding: Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820755. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Accelerate Diagnostics S.L., Abbott, Bio-Rad Laboratories, BD Switzerland Sàrl, and The Wellcome Trust Limited https://value-dx.eu/
Sponsor: UMC Utrecht (Netherlands). Currently in process of
sponsorship transfer to Penta Network.
PI: CPrat and Julia Bielicki. WP4b co leads
Towards an improvement in diagnostics and treatment strategies for TB control. (ADVANCE-TB)
Funding entity: COST Action. Horizon 2020. Reference: CA21164
From: 2022 to: 2026
PI: Alicia Lacoma
Grant Holder Scientific Coordinator: José Domínguez
Grant Awarding Coordinator: Cristina Prat-Aymerich
Hacia una mejora en las estrategias de diagnóstico y tratamiento y una mejor comprensión del impacto de los factores extrínsecos para el control de la tuberculosis. ADVANCE-TB
Funding entity: Instituto de Salud Carlos III. Reference: PI22/01834
From: 2023 to: 2026
Facing tuberculosis through urinary biomarkers
Funding entity: AGAUR. Reference: PRODUCTE-0050
From: 2023 to: 2024
PI: J. Domínguez
Vaezipour N, Fritschi N, Brasier N, Bélard S, Domínquez J, Tebruegge M, Portevin D, Ritz N. Towards accurate point-of-care tests for tuberculosis in children. Pathogens. 2022, 11, 327. DOI: 10.3390/pathogens11030327.
Starshinova A, Kudryavtsev I, Malkova A, Zinchenko Y, Karev V, Kudlay D, Glushkova A, Starshinova A, Dominguez J, Villar-Hernández R, Dovgalyk I, Yablonskiy P. Molecular and Cellular Mechanisms of M.tuberculosis and SARS-CoV-2 Infections - Unexpected Similarities of Pathogenesis and What to expecT from co-infection? International Journal of Medical Sciences. 2022. 17;23(4):2235. DOI: 10.3390/ijms23042235.
Altet N, Latorre I, Jiménez-Fuentes MA, Soriano-Arandes A, Villar-Hernández R, Milà C, Rodríguez-Fernández P, Muriel B, Comella-del-Barrio P, Godoy P, Millet JP, De Souza-Galvão ML, Jiménez-Ruiz CA, Dominguez J, on behalf of PII Smoking SEPAR Working Group. Impact of tobacco smoking and second-hand smoke exposure on Mycobacterium tuberculosis infection in children and adolescents. Journal of Clinical Medicine. 2022. 11, 2000. DOI: 10.3390/jcm11072000
Iem V, Xangsayarath P, Chittamany P, Suthepmany S, Siphanthong S, Somphavong S, Kontogianni K, Dodd J, Khan JAM, Dominguez J, Wingfield T, Creswell J, Cuevas LE. Pooling samples to increase testing capacity with Xpert Xpress SARS-CoV-2 during the Covid-19 pandemic in Lao People's Democratic Republic. Plos One, 2022. 29;17(9):e0275294. DOI: 10.1371/journal.pone.0275294. eCollection 2022
Iem V, Chittamany P, Suthepmany S, Siphanthong S, Somphavong S, Kontogianni K, Dodd J, Khan JAM, Dominguez J, Wingfield T, Creswell J, Cuevas LE. Pooling sputum for Xpert MTB/RIF and Xpert Ultra testing during the Covid-19 pandemic in Lao People's Democratic Republic. PLOS Global Public Health, 2022. 2(4): e0000116. DOI: 10.1371/journal.pgph.0000116
AIem V, Chittamany P, Suthepmany S, Siphanthong S, Somphavong S, Kontogianni K, Dodd J, Khan JAM, Dominguez J, Wingfield T, Creswell J, Cuevas LE. Pooled testing of sputum with Xpert MTB/RIF and Xpert Ultra during tuberculosis active case finding campaigns in Lao People's Democratic Republic. BMJ Global Health, 2022. 7(2):e007592. DOI: 10.1136/bmjgh-2021-007592
Díaz-Fernández S†, Villar-Hernández R†, Stojanovic Z†, Fernández-Sanmartín MA, De Souza-Galvão ML, Tolosa G, Sánchez-Montalva A, Abad J, Jiménez-Fuentes MA, Safont G, Romero I, Sabrià J, Prat C, Domínguez J†, Latorre I†. Study of CD27, CD38, HLA-DR, and Ki-67 immune profiles for the characterization of active tuberculosis, latent infection and end of treatment. Frontiers en Microbiology, 2022. 22;13:88531 DOI: 10.3389/fmicb.2022.885312
Stojanovic Z, Gonçalves-Carvalho F, Marin A, Abad-Capa J, Domínguez J, Latorre I, Lacoma A, Prat-Aymerich C. Advances in diagnostic tools for respiratory tract infections. From tuberculosis to COVID19: changing paradigms? ERJ Open Research 2022. 12;8(3):00113-2022. DOI: 10.1183/23120541.00113-2022
Nicole L Messina, Susie Germano, Rebecca McElroy, Rajeev Rudraraju, Rhian Bonnici, Laure F Pittet, Melanie R Neeland, Suellen Nicholson, Kanta Subbarao, Nigel Curtis; BRACE trial. Off-target effects of bacillus Calmette-Guérin vaccination on immune responses to SARS-CoV-2: implications for protection against severe COVID-19. Clin Transl Immunology. 2022 Apr 22;11(4):e1387. DOI: 10.1002/cti2.1387. eCollection 2022.
Safont G†, Latorre I†, Villar-Hernández R, Stojanovic Z, Marín A, Pérez-Cano C, Lacoma A, Molina-Moya B, Solis AJ, Armestar F, Matllo J, Díaz-Fernández S, Cendón A, Sokalchuk J, Tolosa G, Casas I, A. Rosell‡ and Dominguez J‡. Measuring T-cell responses against SARS-CoV-2 is of utility for disease and vaccination management. Journal of Clinical Medicine 2022. 30;11(17):5103. DOI: 10.3390/jcm11175103
J. Domínguez, M. Boeree, E. Cambau, D. Chesov, F. Conradie, V. Cox, K. Dheda, A. Dudnyk, M. Farhat, S. Gagneux, M. P. Grobusch, M. Groeschel, L. Guglielmetti, I. Kontsevaya, B. Lange, Fv. Leth, C. Lienhardt, A. Mandalakas, F. Maurer, M. Merker, P. Miotto, B. Molina-Moya, S. Niemann, F. Morel, N. Veziris, A. Whitelaw, C.R. Horsburgh*, C. Lange*, for the TBnet and RESIST-TB networks. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement. The Lancet Infectious Diseases. 2023. 23(4): E122-E137. DOI: 10.1016/S1473-3099(22)00875-1
Hamada Y, Gupta RK, Quartagno M, Izzard A, Acuna-Villaorduna C, Altet N, Diel R, Dominguez J, Floyd S, Gupta A, Huerga H, Jones-López EC, Kinikar A, Lange C, van Leth, Liu Q, Lu W, Lu P, Latorre I, Martinez L, Kimbung Mbandi S, Muñoz L, Sánchez-Padilla E, Paradkar M, Scriba T, Sester M, Shanaube K, Sharma SK, Sloot R, Sotgiu G, Thiruvengadam K, Vashishtha R, Abubakar I, Rangaka. Predictive performance of interferon-gamma release assays and the tuberculin skin test for incident TB than the tuberculin skin test: An individual participant data meta-analysis. eClinicalMedicine. 2023, 56:101815. DOI: 10.1016/j.eclinm.2022.101815.
Wheatley RM, Caballero JD, van der Schalk TE, De Winter FHR, Shaw LP, Kapel N, Recanatini C, Timbermont L, Kluytmans J, Esser M, Lacoma A, Prat-Aymerich C, Oliver A, Kumar-Singh S, Malhotra-Kumar S, Craig MacLean R. Gut to lung translocation and antibiotic mediated selection shape the dynamics of Pseudomonas aeruginosa in an ICU patient. Nat Commun. 2022 Nov 22;13(1):6523. DOI: 10.1038/s41467-022-34101-2.
Montagut EJ, Acosta G, Albericio F, Royo M, Godoy-Tena G, Lacoma A, Prat C, Salvador JP, Marco MP. Direct Quantitative Immunochemical Analysis of Autoinducer Peptide IV for Diagnosing and Stratifying Staphylococcus aureus Infections. ACS Infect Dis. 2022 Mar 11;8(3):645-656. DOI: 10.1021/acsinfecdis.1c00670. Epub 2022 Feb 17.
Gomes-Fernandes M, Gomez AC, Bravo M, Huedo P, Coves X, Prat-Aymerich C, Gibert I, Lacoma A, Yero D. Strain-specific interspecies interactions between co-isolated pairs of Staphylococcus aureus and Pseudomonas aeruginosa from patients with tracheobronchitis or bronchial colonization. Sci Rep. 2022 Mar 1;12(1):3374. DOI: 10.1038/s41598-022-07018-5.
Additional noteworthy activities of the research activity that we want to point out are related with Dissemination, Social Impact, Research Transference and Excellence Indicators.
Regarding dissemination, it is important to point out that all the Research Group activities are posted in the web of the institution (www.germanstrias.org), and the twitter, Instagram, Facebook and LinkedIn accounts (@Oneandahalf_Lab; @innova4tb). The social networks accounts allow a dissemination of our research results and scientific activities to the Society in a fast and accessible way.
Actions that will have social impact are a priority for our research group. As we have previously explained we lead INNOVA4TB, an H2020 RISE consortium, where 3 partners are from Ukraine and 1 from Moldova. We have also applied to a COST application (ADVANCE-TB consortium) where partners from Ukraine, Moldova, Georgia, Armenia, North Macedonia, Romania, and even Nigeria are involved. One of the main objectives of these consortiums is to favor the exchanges of staff between institutions, in order to improve their professional careers. This action has a clear social impact, because it improves the quality of the research in all the country partners improve TB control, and helps young scientists and physicians in their career development, especially in Eastern countries and especially in this threatening times.
The group has a pro-active tech transfer behavior. The group has three patents in national phases. Two of them are licensed, and the third is in negotiations with a IVD Company. In all cases the Group has been invited to participate in the co-development of the final product. In one case, one person of the Group was working one full year in the R+D department of the company, and now will be hired for be in charge of the last steps of the market release.
Finally, as indicator of excellent research, to note that the papers published by the group reached more than 1000 citations.
Public engagement in Research and Innovation. The Group is establishing participatory multi-actor dialogues between researchers, policy makers, industry and civil society organizations, NGOs, and citizens in order to define the scientific research priorities.
In 2021 we organized, with the collaboration TB-REP 2.0 a symposium for discussing about the role of the civil society in the TB diagnostic and management. TB-REP 2.0 is a multi-country program covering 11 countries in Eastern Europe region. Representatives of more than 25 small and medium NGOs from Eastern Europe and Euro-Asia countries participated in the event. In the symposium was stated the need of non-invasive methods that provide rapid results are key for reducing the burden of the disease, reduce the stigma that patients suffer, and increase the well-being of the citizens and the society.
The group also participated in 2021 in an international on-line course about Community Engagement in TB Research & Development: Looking for innovations, oriented to civil society that was also organized in collaboration with TB-REP 2.0. The Group discussed with the representatives of the civil society about the preventive therapy of tuberculosis, and the needs of diagnostics and vaccines. These actions contribute to building a more scientifically literate society able to actively participate in and support democratic processes, and science and technology developments. The group plan to continue in contact with the NGOs for involving them in the research strategies of the Group. It is also planned continue with outreach activities. Continuous information will be released from the Group through the social networks (Twitter, LinkedIn, Instagram and Facebook), and conventional media (Newspaper, radio and TV).
Enabling easier access to scientific results. The group prioritize the publication of the results in open access, as a core strategy of the Group to improve knowledge communication, making research findings available free of charge for readers, and improving dissemination of the research. On the other hand, the group has a Research Data Management Plan (DMP). The group commits to follow the guidelines as outlined by the EC, Science Europe, and national requirements. We outline handling of research data and the objects on which the data is based, is carefully planned, documented, and described, which will allow the integrity and reproducibility of scientific results. The Data Management follows the FAIR data principles. The group support the development and consolidation of the European Open Science Cloud (EOSC) as a web of FAIR data. Data generated is available under the CC BY or CC 0 license. Following current legislation [Regulation (EU) 2016/679 of Parliament European Council and of the Council of April 27, 2016 on Data Protection (RGPD)], all clinical data is treated confidentially. The access to the data is granted only for research purposes. The data is stored in a REDCap (Research Electronic Data Capture) database, deposited in IGTP servers. REDCap is a secure web application for building and managing online surveys and databases.
Take up of gender in R&D content and process. The research group has created an environment that promotes responsible conduct and fosters integrity by individual researchers. Gender policies are established and will continuously monitor structures, processes and procedures, which would: a) Give equal skills to both men and women; b) Encourage respect for everyone, especially women, involved in the research environment; c) Promote productive interactions between all research staff irrespective of gender.
The constitution of the group is almost 50% men (9) and women (11). The gender balance in decision-making is assured, all leaders of the Experimental Research Teams are women; and the 8 of 12 researchers of the Clinical Research Team are also women. The gender issue is also considered in the research design and methodologies. Tuberculosis is affecting a large amount of population, and the incidence in women is increasing, probably associated to other risk factors. Therefore, the group will make all efforts to address this issue.
However, the group will go one step further. The group is going to constitute, in the framework of the INNOVA4TB consortium, the Equal Opportunities Commission (EOC) that will take care of gender balance, but also will work towards the elimination of discrimination on the ground's marital status, pregnancy, breastfeeding, disability, family status and race.
Take up of ethics in R&D content and process: Ethics is an integral part of research from the beginning to the end. Ethical research conduct implies the application of fundamental ethical principles and legislation to scientific research. The group will look after for the avoidance of any breach of research integrity, which means, in particular, avoiding fabrication, falsification, plagiarism or other research misconduct.
We have the ethics approval from the different Ethics Committee institutions participating in all our studies. The group complies with the local statutes and adhere to local ethical guidelines. The projects complies with the WMA Declaration of Helsinki (Fortaleza,2013); the Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine (Oviedo, 4 April 1997) (Oviedo Bioethics Convention); the EU Directive 2005/28/EC of 8 April 2005 laying down principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use as well as the requirements for authorization of the manufacturing or importation of such products (OJ L 91, 9.4.2005, p. 13), the EU Regulation No 536/2014 of the European Parliament and of the Council on clinical trials on medicinal products for human use, repealing Directive 2001/20/EC (OJ L 158, 27.5.2014). The Group will also follow the recommendations of the European Textbook on Ethics in Research from the European Commission - EUR 24452 EN - 2010.
Formal and informal science education. Building capacities and developing innovative ways of connecting science to society is one of our priorities. This will help to make science more attractive to young people, increase society's appetite for innovation, and open up further research and innovation activities. In this sense the group has planned the following actions: 1) Press releases to newspapers and feature articles in magazines. 2) Presentation of results and training actions in local TV and radio. 3) Release updated Group information in official webpage (www.germanstrias.org) and social networks (twitter and Facebook). 4) Specific actions in press, and open conferences the World TB Day (24th of March). 5) High school conferences. 6) Participation in the "Open Researcher's Night" and "Science Open Day".
In 2021, the group participated in the project title "European Performing Science Night (EPSN)" lead by la Fundació Èpica La Fura dels Baus, granted by H2020 programme (H2020-MSCA-NIGHT-2020bis). It is an initiative whose main objective is to bring researchers closer to the public and encourage their recognition, their work and the value they bring to society. To carry out these goals, the project proposes different actions that combine science, art and technology. In the first place, EPSN develops a workshop aimed at participating researchers in which, through co-creation methodologies, the generation of synergies between groups and disciplines will be promoted, on the one hand, and communication with the audience, on the other hand. Second, a co-creation workshop aimed at scientists, technologists and artists that will take place from September 13 to 25. This workshop will culminate with a public performance based on the challenges and research raised by the experts participating in the first workshop. Finally, the results obtained during the workshop will be presented in a public session that will include exhibitions, interactive experiences and talks. All this aimed at promoting the values of science, demonstrating the impact and attractiveness of researchers' work to motivate young people to embark on research careers.
Un assaig internacional ha investigat els possibles efectes de reforç immunitari de la vacuna BCG contra la tuberculosi en la COVID-19. Els resultats mostren que el risc de desenvolupar la malaltia durant els sis primers mesos després de la vacunació no es va reduir en els participants com s'esperava al principi. Gairebé 4.000 treballadors sanitaris van participar en l'assaig BRACE en 36 centres de cinc països, entre ells l'Hospital Germans Trias. Investigadors d'un dels grups de recerca sobre tuberculosi de l'IGTP van participar en el desenvolupament de l'estudi, que s'ha publicat en el New England Journal of Medicine.
Un consens internacional destaca la importància de les proves moleculars de resistència als antibiòtics en el maneig de la tuberculosi
Un grup multidisciplinar d'experts en tuberculosi de les xarxes TBnet i RESIST-TB han arribat a un consens sobre aspectes clau relacionats amb la predicció molecular de la sensibilitat o la resistència als antibiòtics de Mycobacterium tuberculosis i les seves implicacions clíniques. El document de consens proporciona orientacions per al disseny de règims terapèutics i l'optimització dels tractaments, i s'ha elaborat amb l'objectiu d'ajudar als clínics a tractar els pacients amb tuberculosi. El treball, publicat a The Lancet Infectious Diseases i liderat pel Dr. José Domínguez de l'IGTP, és una actualització d'una declaració similar de l'any 2016.